Vendor Intelligence Report: Evolve BioPep

Published 3 Jul 2026. 24-page investigative report on who is behind Evolve BioPep: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 11 Finnrick lab tests, Evolve BioPep posts 7 pass / 4 fail, an overall pass rate of 64%. That average hides a product-specific record: Tirzepatide is the comparatively strongest tested choice, Retatrutide is mixed enough to require batch verification before buying, and Tesamorelin is an avoid-until-updated signal on the present data. The full report also shows why the public pass/fail view is incomplete: ratings can contract under stricter grading for buyers who care about fill and dosing precision.

The bigger buyer issue is a transparency mismatch. The homepage presents third-party ISO-17025 testing and U.S. domestic supplier/manufacturer language, while the source trail reviewed in the report points to manufacturer-origin COAs and no named independent lab-verification path in the supplied record. That does not mean every vial is bad; it means vendor-published paperwork should not be treated as independent batch assurance without outside verification.

Evolve BioPep's footprint is broader than a single peptide shop. The investigation maps a Wyoming LLC, public operator-attribution records, a Maine backend-services layer, a sister storefront, a partner-storefront platform, and a merchandise channel. It also documents an expanded referral economy, undisclosed Reddit referral paths, official social promotion, and payment-rail disruption followed by a later checkout change whose processor was not publicly identified.

Inside the full report:

  • Finnrick rating overview, methodology-divergence chart, and spark-grid trajectories for all three tested products
  • Testing-transparency review comparing homepage ISO-17025 language with the manufacturer-origin COA trail
  • Corporate identity packet combining Wyoming LLC records, BBB attribution, APA membership signals, and registered-agent address analysis
  • Retail-footprint map covering the primary shop, sister storefront, partner hub, backend-services site, Bangor agency, and merch channel
  • Affiliate and promotion scan covering coupon-site disclosure, Reddit referral paths, official TikTok/X pushes, and buyer-safety implications
  • Chronology of public launch, payment-processor disruption, partner-platform expansion, and unresolved research limits

Risk assessment

  • Testing-transparency misrepresentation risk — high: All products: site claims ISO-17025 third-party testing, but the supplied COA trail points to SRY/PGB manufacturer documents and no named independent lab.
  • Retatrutide and Tesamorelin test-performance risk — high: Retatrutide: 4 tests, 2 pass / 2 fail, 74.71%; Tesamorelin: 1 test, 0 pass / 1 fail, 44.39%; Tirzepatide is comparatively stronger.
  • Franchise and brand-channel opacity risk — medium: EvolveBioPepTech enables partner storefronts; evolvepep.com is a sister storefront; no public authorized-partner list was verified.
  • Affiliate-promotion risk — medium: Expanded referral economics plus 3 undisclosed Reddit referral placements increase the risk that recommendations are marketing rather than quality comparisons.
  • Corporate-accountability opacity risk — medium: Wyoming registered-agent LLC, Maine technology/operator footprint, limited public officer data, and routed phone signal make accountability less direct for buyers.
  • Payment-processor instability risk — medium: Poynt terminated the account within 24 hours in July 2025; a new processor was indicated around June 22, 2026 but not publicly identified.